Clinical trial
An Open Label, Non-randomized Treatment Protocol of Tipranavir Co-administered With Low-dose Ritonavir (TPV/r) in Protease Inhibitor-experienced Patients With HIV-1 Infection (the Tipranavir Expanded Access Program)
NCT00097799 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open Label, Non-randomized Treatment Protocol of Tipranavir Co-administered With Low-dose Ritonavir (TPV/r) in Protease Inhibitor-experienced Patients With HIV-1 Infection (the Tipranavir Expanded Access Program)
- Lead sponsor
- Boehringer Ingelheim
- Phase
- Expanded access
- Overall status
- Approved for marketing
- Start date
- December 31, 2004
- Completion date
- Not reported
- Enrollment
- Not reported
- Sites
- 115
Conditions
As the registry lists them; a condition with its own page is linked.